I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
Medium term milestones, page-90
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.27 |
Change
-1.370(6.33%) |
Mkt cap ! $2.588B | |||
| Open | High | Low | Value | Volume |
| $21.62 | $21.63 | $20.24 | $11.01M | 531.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1111 | $20.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.28 | 338 | 1 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.37 |
Change
-1.370 ( 5.24 %) |
||||
| Open | High | Low | Volume | ||
| $21.61 | $21.62 | $20.25 | 138748 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| NEU (ASX) Chart |